The order comes as part of litigation against the Food and Drug Administration, filed by the state of Louisiana, regarding the agency’s decision to remove in-person screening requirements for dispensing the abortion drug.
Mail-order abortion has been a major concern in the abortion debate since the Supreme Court overturned Roe v. Wade in 2022. Mifepristone is used in nearly two-thirds of the more than 1.1 million abortions in the United States each year.
This is a developing story.
Continue reading
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!